Published online before print June 27, 2002, doi: 10.1161/01.RES.0000027530.58419.82
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 3, 2001
Revised on June 11, 2002
Accepted on June 12, 2002
Cardiac Dysfunction in Hypertrophic Cardiomyopathy Mutant Tropomyosin Mice Is Transgene-Dependent, Hypertrophy-Independent, and Improved by ß-Blockade
Daniel E. Michele ;
From the Departments of Physiology (D.E.M., K.E.H., J.M.M.), Pediatric Cardiology (C.A.G.), and Surgery (M.V.W.), University of Michigan, Ann Arbor, Mich.
* To whom correspondence should be addressed. E-mail: metzgerj{at}umich.edu.
Familial hypertrophic cardiomyopathy (FHC) has been linked to mutations in proteins of the cardiac contractile apparatus, including 
-tropomyosin (Tm). Mice expressing Tm in the heart were developed to determine the effects of FHC mutant Tm on cardiac structure and function from single cardiac myocytes to whole organ function in vivo. Expression of E180G mutant Tm did not produce cardiac hypertrophy or detectable changes in cardiac muscle morphology. However, E180G mutant Tm expression increased the Ca2+ sensitivity of force production in single cardiac myocytes in a transgene expression--dependent manner. Contractile dysfunction in single myocytes manifested organ level dysfunction, as conductance-micromanometry showed E180G Tm mice had significantly slowed relaxation (diastolic dysfunction) under physiological conditions. The diastolic dysfunction in E180G Tm mice was no longer evident during ß-blockade because propranolol eliminated the effect of E180G Tm to slow myocardial relaxation. Cellular and organ level dysfunction were evident in E180G Tm mice in the absence of significant cardiac structural abnormalities normally associated with FHC. These findings therefore suggest that diastolic dysfunction in FHC may be a direct consequence of FHC mutant protein expression. In addition, because diastolic dysfunction in E180G Tm mice is dependent on inotropic status, cardiovascular stress may play an important role in FHC pathogenesis.
Key words: tropomyosin • hypertrophic cardiomyopathy • calcium • heart • mice
This article has been cited by other articles:
 |
|
 |
|
  S. Morimoto Expanded Spectrum of Gene Causing Both Hypertrophic Cardiomyopathy and Dilated Cardiomyopathy Circ. Res., August 14, 2009; 105(4): 313 - 315. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wagner, C. Jehl-Pietri, P. Lopez, J. Murdaca, C. Giordano, C. Schwartz, P. Gounon, S. N. Hatem, P. Grimaldi, and K.-D. Wagner Peroxisome proliferator-activated receptor {beta} stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin Cardiovasc Res, July 1, 2009; 83(1): 61 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Palpant, L. G. D'Alecy, and J. M. Metzger Single histidine button in cardiac troponin I sustains heart performance in response to severe hypercapnic respiratory acidosis in vivo FASEB J, May 1, 2009; 23(5): 1529 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Morimoto Sarcomeric proteins and inherited cardiomyopathies Cardiovasc Res, March 1, 2008; 77(4): 659 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Gunning, G. O'neill, and E. Hardeman Tropomyosin-Based Regulation of the Actin Cytoskeleton in Time and Space Physiol Rev, January 1, 2008; 88(1): 1 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Westermann, B. C. Knollmann, P. Steendijk, S. Rutschow, A. Riad, M. Pauschinger, J. D. Potter, H.-P. Schultheiss, and C. Tschope Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy Eur J Heart Fail, March 1, 2006; 8(2): 115 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Chang, K. Harada, M. J. Ackerman, and J. D. Potter Functional Consequences of Hypertrophic and Dilated Cardiomyopathy-causing Mutations in {alpha}-Tropomyosin J. Biol. Chem., October 7, 2005; 280(40): 34343 - 34349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sipola, K. Lauerma, P. Jaaskelainen, M. Laakso, K. Peuhkurinen, H. Manninen, H. J. Aronen, and J. Kuusisto Cine MR Imaging of Myocardial Contractile Impairment in Patients with Hypertrophic Cardiomyopathy Attributable to Asp175Asn Mutation in the {alpha}-Tropomyosin Gene Radiology, September 1, 2005; 236(3): 815 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Wernicke, C. Thiel, C. M. Duja-Isac, K. V. Essin, M. Spindler, D. J. R. Nunez, R. Plehm, N. Wessel, A. Hammes, R.-J. Edwards, et al. {alpha}-Tropomyosin mutations Asp175Asn and Glu180Gly affect cardiac function in transgenic rats in different ways Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2004; 287(3): R685 - R695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Coutu, C. N. Bennett, E. G. Favre, S. M. Day, and J. M. Metzger Parvalbumin Corrects Slowed Relaxation in Adult Cardiac Myocytes Expressing Hypertrophic Cardiomyopathy-Linked {alpha}-Tropomyosin Mutations Circ. Res., May 14, 2004; 94(9): 1235 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Layland, D. J. Grieve, A. C. Cave, E. Sparks, R J. Solaro, and A. M. Shah Essential role of troponin I in the positive inotropic response to isoprenaline in mouse hearts contracting auxotonically J. Physiol., May 1, 2004; 556(3): 835 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Heller, M. Nili, E. Homsher, and L. S. Tobacman Cardiomyopathic Tropomyosin Mutations That Increase Thin Filament Ca2+ Sensitivity and Tropomyosin N-domain Flexibility J. Biol. Chem., October 24, 2003; 278(43): 41742 - 41748. [Abstract] [Full Text] [PDF]
|
|